Poseida Therapeutics, Inc.
poseida.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2025.
10-Q for Q3 FY2024, filed Nov 7, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops allogeneic CAR-T therapies for patients with cancer and gene therapies for patients with rare diseases.
10-K for FY2023, filed Mar 7, 2024We are a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases. We…View ↗
Within cell therapy, we believe our technologies allow us to create product candidates with engineered cells, containing a high percentage…View ↗
We are internally focused on in vivo gene therapy. Our lead programs, including P-FVIII-101, a non-viral approach, combine piggyBac…View ↗
How Did They Make Money?
Poseida earns money mainly from collaboration and license agreements: partners pay upfront for intellectual-property licenses, fund research services billed as work is performed, and may owe milestone payments and royalties tied to product sales.
10-K for FY2023, filed Mar 7, 2024The Company’s revenues to date have been generated primarily through collaboration and license agreements. The Company’s collaboration and…View ↗
The Company generates revenue from licensing its intellectual property including know-how and development and commercialization rights.…View ↗
The Company generates revenue from research and development services it provides to its customers in connection with the licensed…View ↗
The Company’s contracts with customers generally include two types of variable consideration: (i) research, development and regulatory…View ↗
Product sales-based royalties under licensed intellectual property are accounted for under the royalty exception. The Company recognizes…View ↗
The Company receives payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration…View ↗
$64.7M
-
10-K for FY2023, filed Mar 7, 2024
$64.7M ↗
Who Were Their Customers?
Pharmaceutical partners license programs and work with Poseida through collaboration agreements; Poseida also provides research and development services under those agreements.
10-K for FY2023, filed Mar 7, 2024In August 2022, we announced a partnership with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or, collectively Roche, in which they…View ↗
Under the Collaboration and License Agreement that we entered into with Roche, or the Roche Collaboration Agreement, Roche made an upfront…View ↗
The Company’s revenues to date have been generated primarily through collaboration and license agreements. The Company’s collaboration and…View ↗
The Company generates revenue from research and development services it provides to its customers in connection with the licensed…View ↗
Did Revenues Turn Into Profits?
No. It lost $123.4M in FY2023.
10-K for FY2023, filed Mar 7, 2024
−$129.5MView ↗
10-K for FY2023, filed Mar 7, 2024
−$123.4MView ↗
10-K for FY2023, filed Mar 7, 2024
−$95.3MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 7, 2024
$20.2MView ↗
- ▲ Now profitable
- vs −$31.8M in Q3 FY2023
-
Jan 8, 2025
Roche completed its acquisition of Poseida
The merger made Poseida a wholly owned subsidiary of Roche.
Sources
8-K, filed Jan 8, 2025
Also on January 8, 2025, following consummation of the Offer, Merger Sub merged with and into the Company, with the Company being the…View ↗
-
Nov 26, 2024
Roche agreed to acquire Poseida
The offer included $9.00 per share in cash and a contingent value right for up to $4.00 per share.
Sources
8-K, filed Nov 26, 2024
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub will (and Parent will cause Merger…View ↗
-
May 1, 2024
Poseida signed a cell-therapy collaboration with Astellas
Xyphos will develop and commercialize products from two solid-tumor programs generated by the collaboration.
Sources
8-K, filed May 1, 2024
On April 30, 2024, Poseida Therapeutics, Inc. (the “Company”) and Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma…View ↗
Cell therapy portfolio
The earlier report describes both autologous and allogeneic CAR-T candidates; the latest describes an allogeneic portfolio and says enrollment in an autologous prostate cancer program stopped.
10-K for FY2020, filed Mar 11, 2021 10-K for FY2023, filed Mar 7, 2024Within cell therapy, we believe our technologies allow us to create product candidates with engineered cells that engraft in the patient’s…View ↗
Partnered hematology programs
The earlier report describes its product-candidate portfolio as wholly owned; the latest says Roche has licensed hematological CAR-T programs and will take over future development after the initial clinical trials.
10-K for FY2020, filed Mar 11, 2021 10-K for FY2023, filed Mar 7, 2024We are a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create…View ↗
Who Did They Compete With?
Competes with Adaptimmune Therapeutics, Allogene, Arcellx, Astellas Pharma, Autolus, Bristol-Meyers Squibb, Caribou Biosciences, Cellectis, Janssen Pharmaceuticals, Juno Therapeutics, Gracell Biotechnologies, Kite Pharma, Legend Biotech, Novartis, Takeda, Amgen, AstraZeneca, F. Hoffman-La Roche, GlaxoSmithKline, and Merck &
10-K for FY2023, filed Mar 7, 2024Due to the promising clinical therapeutic effect of CAR-T product candidates in clinical trials, we anticipate direct competition from…View ↗
Loading...
